WorldStage– Fidson Healthcare Plc has notified the Nigerian Exchange Limited (NGX) and the investing public that its Board of Directors will hold its 120th meeting on Thursday, 22 October 2026.
A key item on the agenda is the consideration and approval of the company’s Unaudited Financial Statements for the third quarter ended 30 September 2026 (2026 Q3 UFS).
In line with NGX listing rules, a closed period restricting trading in the company’s shares by insiders has been in effect since 1 October 2026 and will remain in force until 24 hours after the results are released to the public.
The upcoming board meeting is significant for investors as it is expected to precede the official release of Fidson’s Q3 2026 performance figures.
Market participants will be watching for updates on revenue growth, profitability, operational efficiency, and any indications of the company’s outlook in the pharmaceutical and healthcare sector.
Fidson Healthcare, a leading Nigerian pharmaceutical manufacturer, remains closely followed by investors due to its position in the consumer healthcare and pharmaceutical space.
The release of the Q3 results following the board meeting could influence near-term sentiment around the stock.Further details will be communicated once the board concludes its deliberations and the financial statements are published.
